Chattem scientific officer
This article was originally published in The Rose Sheet
Executive Summary
Donald Riker, PhD, named VP-R&D and chief scientific officer, replacing former R&D head Elaine Morefield, PhD, who left in July to pursue other interests. Creation of CSO post signals greater emphasis on R&D, Chattem says. Riker brings almost 20 years experience in clinical-regulatory affairs, licensing and OTC product development at Procter & Gamble and Richardson-Vicks, working on brands such as NyQuil, DayQuil and Vicks. He has served as associate director and P&G fellow at global healthcare facility in Mason, Ohio, since 1992...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.